Iversen, Katrine Fladeland http://orcid.org/0000-0003-4494-9034
Nederby, Line
Lund, Thomas
Plesner, Torben
Funding for this research was provided by:
Lægeforeningen (2019-3780/67)
Fonden til Lægevidenskabens Fremme (19-L-0185)
Region of Southern Denmark (2019 19/12124/A233)
Overlæge Jørgen Werner Schous og hustru, ELse-Marie Schou, født Wonges fond
Article History
Received: 25 February 2022
Accepted: 4 June 2022
First Online: 9 August 2022
Declarations
:
: Katrine Fladeland Iversen, Line Nederby, and Thomas Lund declare no conflicts of interest. Torben Plesner is serving as an advisor for Janssen, Celgene, Takeda, Oncopeptides, Genentech, CSL Behring and AbbVie and receives research support from Janssen, Genmab, Celgene, Takeda, Oncopeptides, Genentech, AbbVie and Roche. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Regional Committees on Health Research Ethics for Southern Denmark (S-20170212, 02Feb2018).
: All patients included signed the informed consent form, which included consent to publish the results.